Benitec Biopharma Inc.: updates and filings

BNTCNASDAQHealthcare · Pharmaceutical Preparations

Price

$7.92

November 20, 2026Market cap $392M

What Ploutos Investor adds for Benitec Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from FY2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 82 daysAround Feb 12, 2027 · for Q4 2027

last Nov 13, 2026next Feb 12, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Sep 14, 2026 latest annualNov 13, 2026 latest quarterly
  • Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 13, 2026Results of operations, amended articles or bylaws
    Form8-K
  • Oct 28, 2026Regulation FD disclosure
    Form8-K
  • Oct 20, 2026Additional annual meeting material
    FormDEFA14A
  • Oct 20, 2026Annual meeting proxy statement
    FormDEF 14A
  • Oct 5, 2026Regulation FD disclosure
    Form8-K
  • Sep 30, 2026Change of auditor
    Form8-K
  • Sep 24, 2026Change of auditor
    Form8-K
  • Sep 21, 2026Filing
    FormEFFECT
  • Sep 14, 2026Shelf registration for future offerings
    FormS-3
  • Sep 14, 2026Annual reportfor the period to Jun 30, 2026
    Form10-K
  • Sep 14, 2026Results of operations
    Form8-K
  • May 29, 2026Officer or director change
    Form8-K
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 14, 2026Results of operations
    Form8-K
  • Apr 3, 2026Letter from the SEC
    FormUPLOAD
  • Mar 20, 2026Correspondence with the SEC
    FormCORRESP
  • Mar 20, 2026Annual report (amendment)for the period to Jun 30, 2025
    Form10-K/A
  • Feb 24, 2026Letter from the SEC
    FormUPLOAD
  • Feb 12, 2026Results of operations
    Form8-K
  • Feb 12, 2026Quarterly reportfor the period to Dec 31, 2025
    Form10-Q
  • Feb 10, 2026Filing
    FormEFFECT
  • Feb 6, 2026Correspondence with the SEC
    FormCORRESP
  • Feb 6, 2026Letter from the SEC
    FormUPLOAD
  • Jan 30, 2026Shelf registration for future offerings
    FormS-3

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 15, 2020.

The full analysis

What do Benitec Biopharma's filings show?

The filings are where every one of Benitec Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.